MX2019006830A - Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. - Google Patents

Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.

Info

Publication number
MX2019006830A
MX2019006830A MX2019006830A MX2019006830A MX2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A MX 2019006830 A MX2019006830 A MX 2019006830A
Authority
MX
Mexico
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
MX2019006830A
Other languages
English (en)
Other versions
MX385562B (es
Inventor
Paul Burkholder Timothy
Alejandro Bauer Renato
Louis Boulet Serge
Gilmour Raymond
James Hahn Patric
Rankovic Zoran
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019006830A publication Critical patent/MX2019006830A/es
Publication of MX385562B publication Critical patent/MX385562B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto, como se define en la presente, o composición farmacéutica que contiene el compuesto, para usar en el tratamiento del cáncer mutante de IDH1 o IDH2 y que tiene la estructura: (formula).
MX2019006830A 2016-12-16 2017-12-08 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. MX385562B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (2)

Publication Number Publication Date
MX2019006830A true MX2019006830A (es) 2019-08-22
MX385562B MX385562B (es) 2025-03-18

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006830A MX385562B (es) 2016-12-16 2017-12-08 Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.

Country Status (37)

Country Link
US (3) US11001596B2 (es)
EP (2) EP3555105B1 (es)
JP (1) JP6793836B2 (es)
KR (1) KR102276022B1 (es)
CN (2) CN115109075B (es)
AU (2) AU2017378060B2 (es)
CA (1) CA3045303C (es)
CL (1) CL2019001551A1 (es)
CO (1) CO2019005287A2 (es)
CR (1) CR20190252A (es)
CY (1) CY1123577T1 (es)
DK (1) DK3555105T3 (es)
DO (1) DOP2019000163A (es)
EA (1) EA036112B1 (es)
EC (1) ECSP19042682A (es)
ES (2) ES2835281T3 (es)
HR (1) HRP20201882T1 (es)
HU (1) HUE052067T2 (es)
IL (1) IL267236B (es)
JO (1) JOP20190142B1 (es)
LT (1) LT3555105T (es)
MA (2) MA53881A (es)
MD (1) MD3555105T2 (es)
MX (1) MX385562B (es)
MY (1) MY197313A (es)
NZ (1) NZ754115A (es)
PE (1) PE20190977A1 (es)
PH (1) PH12019501328B1 (es)
PL (1) PL3555105T3 (es)
PT (1) PT3555105T (es)
RS (1) RS61108B1 (es)
SA (1) SA519401897B1 (es)
SI (1) SI3555105T1 (es)
TN (1) TN2019000158A1 (es)
UA (1) UA123640C2 (es)
WO (1) WO2018111707A1 (es)
ZA (1) ZA201903125B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9771349B2 (en) 2014-09-19 2017-09-26 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MX372986B (es) 2014-09-19 2020-03-31 Forma Therapeutics Inc Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317322B2 (en) 2014-09-19 2020-09-17 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
LT3194376T (lt) 2014-09-19 2019-02-25 Forma Therapeutics, Inc. Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3555105B1 (en) * 2016-12-16 2020-10-28 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US12521395B2 (en) 2019-11-08 2026-01-13 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors
WO2021194953A1 (en) 2020-03-23 2021-09-30 Eli Lilly And Company Method for treating idh1 inhibitor-resistant subjects
BR112022017394A2 (pt) 2020-03-23 2022-10-18 Lilly Co Eli Terapia de combinação com um inibidor de idh mutante
AU2021241470B2 (en) * 2020-03-23 2023-12-14 Board Of Regents, The University Of Texas System Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤
US12559505B2 (en) 2020-06-28 2026-02-24 Wigen Biomedicine Technology (shanghai) Co., Ltd. IDH mutant inhibitor and use thereof
EP4181927A1 (en) * 2020-07-20 2023-05-24 Eli Lilly and Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
EP4337217A1 (en) 2021-06-09 2024-03-20 Eli Lilly and Company Method for treating idh inhibitor-resistant subjects
CA3217608A1 (en) 2021-06-15 2022-12-22 Yuli Xie Idh mutant inhibitor and use thereof
WO2023018955A1 (en) 2021-08-13 2023-02-16 Eli Lilly And Company Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771337B1 (en) 2011-09-27 2017-08-02 Novartis AG 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CN107405687A (zh) * 2015-04-24 2017-11-28 哈利伯顿能源服务公司 制作陶瓷或金属间化合物零件的方法
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
CN109311863B (zh) * 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂
EP3555105B1 (en) * 2016-12-16 2020-10-28 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Also Published As

Publication number Publication date
PH12019501328A1 (en) 2020-02-24
PT3555105T (pt) 2020-12-21
PL3555105T3 (pl) 2021-05-17
EA201991161A1 (ru) 2019-11-29
CN110072867A (zh) 2019-07-30
MY197313A (en) 2023-06-13
ECSP19042682A (es) 2019-06-30
AU2020260493A1 (en) 2020-11-26
CN110072867B (zh) 2022-07-08
MX385562B (es) 2025-03-18
MA47399B1 (fr) 2021-02-26
AU2017378060A1 (en) 2019-05-30
CL2019001551A1 (es) 2019-10-25
RS61108B1 (sr) 2020-12-31
AU2020260493B2 (en) 2021-09-09
CA3045303C (en) 2022-05-17
EA036112B1 (ru) 2020-09-29
EP3555105B1 (en) 2020-10-28
HUE052067T2 (hu) 2021-04-28
HRP20201882T1 (hr) 2021-01-22
ES2941631T3 (es) 2023-05-24
CY1123577T1 (el) 2022-03-24
JOP20190142A1 (ar) 2019-06-13
JP2020502157A (ja) 2020-01-23
US20200079791A1 (en) 2020-03-12
US20210230185A1 (en) 2021-07-29
MD3555105T2 (ro) 2021-01-31
IL267236A (en) 2019-08-29
PH12019501328B1 (en) 2023-05-12
CA3045303A1 (en) 2018-06-21
CR20190252A (es) 2019-08-26
SA519401897B1 (ar) 2022-07-28
KR102276022B1 (ko) 2021-07-13
DK3555105T3 (da) 2020-11-09
WO2018111707A1 (en) 2018-06-21
EP3763717B1 (en) 2023-03-08
EP3763717A1 (en) 2021-01-13
JP6793836B2 (ja) 2020-12-02
US11629156B2 (en) 2023-04-18
EP3555105A1 (en) 2019-10-23
CO2019005287A2 (es) 2019-05-31
CN115109075A (zh) 2022-09-27
US11649247B2 (en) 2023-05-16
PE20190977A1 (es) 2019-07-09
IL267236B (en) 2020-08-31
TN2019000158A1 (en) 2020-10-05
UA123640C2 (uk) 2021-05-05
ES2835281T3 (es) 2021-06-22
SI3555105T1 (sl) 2020-12-31
JOP20190142B1 (ar) 2023-03-28
NZ754115A (en) 2021-07-30
CN115109075B (zh) 2024-09-20
DOP2019000163A (es) 2019-07-15
ZA201903125B (en) 2024-08-28
MA47399A (fr) 2019-10-23
LT3555105T (lt) 2021-01-11
BR112019009648A2 (pt) 2019-09-10
MA53881A (fr) 2022-04-27
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
KR20190077539A (ko) 2019-07-03
AU2017378060B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2019006830A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
GEAP202215540A (en) Pcsk9 antagonist compounds
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112018004620A2 (pt) moduladores da expressão de kras
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CO2022000481A2 (es) Inhibidores de enzimas
NZ758177A (en) Modulators of pcsk9 expression
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CO2022000270A2 (es) Inhibidores de enzimas
EA201792287A1 (ru) Способы лечения рака
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CR20150148A (es) Azaindolinas
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
UY38472A (es) Moduladores de la expresión de foxp3